VECTIVBIO
VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to pursuing rare diseases with well-defined biology that can be targeted with best-in-disease therapies that have the potential to meaningfully transform and improve the lives of patients and their families, not just provide an incremental improvement or benefit over the standard-of-care. It was founded as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia. VectivBio was incorporated in 2019 and is based in Basel, Switzerland.
VECTIVBIO
Industry:
Biotechnology Health Care Medical
Founded:
2019-01-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.vectivbio.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
274 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
BforCure
BforCure is a biotech engaged in the manufacture of high speed biosensing solutions such as CHRONOS PCR.
Coramaze Technologies
Coramaze Technologies, a medical device company, offers a minimally-invasive valve repair system for people with heart diseases.
eureKARE
eureKARE is focused on financing and building biotechnology companies in the cutting-edge fields of microbiome and synthetic biology.
Exo Lab Italia
Exo Lab Italia is a biotechnological company which uses vegetable nanovesicles deriving from organic fruit and vegetables.
Gate2Brain
Gate2Brain is a biotech company to improve drug delivery with peptide-based patented technology.
Healx
Healx is an AI-powered, patient-inspired technology company, pioneering the next generation of drug discovery for rare diseases.
Olgram
Olgram is a biotechnology company that develops marine molecules for the prevention and control of chronic bacterial infections.
OncoDiag
OncoDiag is a French biotechnology company based in Normandy at one hour from Paris and Rouen cities.
OneLIFE
OneLIFE provides patented technologies to detect and treat bacterial biofilm on medical devices such as surgical instruments and endoscopes.
ORIG3N
ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases.
Q32 Bio
Q32 Bio is a biotechnology company that develops treatments for patients with severe autoimmune and inflammatory diseases.
SNIPR Biome
SNIPR Biome is a operator of a discovery stage biotech company intended to revolutionize the treatment of microbial diseases.
SolasCure
Solascure is a biotechnology company focused on the development of fit for purpose, efficacious wound care products.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-08-31 | Comet Therapeutics | Comet Therapeutics acquired by VectivBio | N/A |
Investors List
Forbion Capital Partners
Forbion Capital Partners investment in Post-IPO Equity - VectivBio
Kreos Capital
Kreos Capital investment in Post-IPO Debt - VectivBio
Cowen Healthcare Investments
Cowen Healthcare Investments investment in Venture Round - VectivBio
Novo Holdings
Novo Holdings investment in Venture Round - VectivBio
OrbiMed
OrbiMed investment in Venture Round - VectivBio
Surveyor Capital
Surveyor Capital investment in Venture Round - VectivBio
Eventide
Eventide investment in Venture Round - VectivBio
Cormorant Capital
Cormorant Capital investment in Venture Round - VectivBio
Bpifrance
Bpifrance investment in Venture Round - VectivBio
Versant Ventures
Versant Ventures investment in Venture Round - VectivBio
Key Employee Changes
Official Site Inspections
http://www.vectivbio.com
- Host name: 172.67.74.109
- IP address: 172.67.74.109
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "VectivBio" on Search Engine
VectivBio - Crunchbase Company Profile & Funding
Legal Name VectivBio AG. Stock Symbol NASDAQ:VECT. Company Type For Profit. Contact Email [email protected]. VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to pursuing rare diseases with well-defined biology that can be targeted with …See details»
Ironwood Enters into Definitive Agreement to Acquire VectivBio, a ...
May 22, 2023 Headquartered in Basel, Switzerland, VectivBio is a clinical-stage biotechnology company focused on the discovery and development of treatments for severe, rare conditions, including Short Bowel Syndrome with Intestinal Failure (SBS-IF) and acute Graft versus Host Disease (aGvHD).See details»
Ironwood Announces the Completion of Squeeze-Out Merger With VectivBio
BOSTON, December 12, 2023--Ironwood Pharmaceuticals, Inc. ("Ironwood") (Nasdaq: IRWD), a GI-focused healthcare company, today announced the successful completion of the squeeze-out merger under...See details»
VectivBio - Funding, Financials, Valuation & Investors - Crunchbase
$399M. in funding over 5 rounds. Their latest funding was raised on Oct 13, 2022 from a Post-IPO Equity round. VectivBio is registered under the ticker NASDAQ:VECT . Their stock opened with $17.00 in its Apr 8, 2021 IPO. VectivBio is funded by 18 investors. OrbiMed and Surveyor Capital are the most recent investors.See details»
Ironwood Announces the Completion of Squeeze-Out Merger With VectivBio
Dec 12, 2023 BOSTON-- (BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (“Ironwood”) (Nasdaq: IRWD), a GI-focused healthcare company, today announced the successful completion of the squeeze-out merger under Swiss law (the “Squeeze-Out Merger”) pursuant to which VectivBio Holding AG (“VectivBio”) has been merged with …See details»
Ironwood and VectivBio Announce the Completion of the Tender …
June 29, 2023. BOSTON & BASEL, Switzerland-- (BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (“Ironwood”) (Nasdaq: IRWD), a GI-focused healthcare company, and VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare ...See details»
VectivBio to be Acquired by Ironwood - Cooley
Basel, Switzerland – May 23, 2023 – Cooley advised VectivBio, a clinical-stage biotech company focused on the discovery and development of treatments for severe, rare gastrointestinal (GI) conditions, on its acquisition by Ironwood, with an estimated aggregate consideration of approximately $1 billion.See details»
VectivBio Reports Full Year 2021 Financial Results and Provides ...
BASEL, Switzerland, April 07, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments...See details»
Ironwood to buy rare disease drugmaker in billion-dollar deal
May 22, 2023 Ironwood Pharmaceuticals plans to buy VectivBio, a Switzerland-based biotechnology company focused on treating rare disorders, in an all-cash deal valued at around $1 billion. Terms hold that Ironwood will pay $17 for each VectivBio share, reflecting a 43% premium to the stock’s price at market’s close Friday.See details»
Christian Meyer, M.D., Ph.D. - VectivBio
Nov 20, 2019 Dr. Christian Meyer is the Chief Operating Officer of VectivBio, bringing more than 20 years of international rare disease drug development leadership and entrepreneurship to the company.See details»
VectivBio AG | LinkedIn
VectivBio AG is a clinical-stage biotechnology company focused on rare diseases with a well-defined biology that can be targeted with transformational therapeutics.See details»
VectivBio Company Profile - Craft
Jul 17, 2023 VectivBio a biotechnology company focused on the discovery, development, and commercialization of treatments for severe rare conditions. It develops transformational medicines for patients with short bowel syndrome-intestinal failure (SBS-IF), as well as for SBS-IF in patients with colon-in-continuity anatomy, and others. Type. Public. Status.See details»
Ironwood Enters into Definitive Agreement to Acquire VectivBio, a ...
May 22, 2023 BOSTON & BASEL, Switzerland, May 22, 2023 -- ( BUSINESS WIRE )--Ironwood Pharmaceuticals, Inc. ("Ironwood") (Nasdaq: IRWD), a GI-focused healthcare company, and VectivBio Holding AG ("VectivBio")...See details»
VectivBio Announces Closing of $54 Million Aggregate
BASEL, Switzerland, June 29, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments...See details»
VectivBio Closes $110 Million Crossover Financing to Advance ... - BioSpace
BASEL, Switzerland, Oct. 15, 2020 /PRNewswire/ -- VectivBio AG, a clinical-stage biotechnology company developing transformational medicines for patients with serious rare diseases, today announced it has closed a $110 million crossover financing from new investors Surveyor Capital (a Citadel company), Cormorant Capital and Eventide Asset …See details»
VectivBio Announces Closing of Comet Therapeutics
BASEL, Switzerland, Sept. 21, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments...See details»
VectivBio Closes $110 Million Crossover Financing to Advance ...
BASEL, Switzerland, Oct. 15, 2020 /PRNewswire/ -- VectivBio AG, a clinical-stage biotechnology company developing transformational medicines for patients with serious rare diseases, today...See details»
VectivBio Announces Closing of $125 Million Underwritten …
BASEL, Switzerland, Oct. 18, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments...See details»
VectivBio Announces Pricing of $30 Million Public Offering
Jun 15, 2022 BASEL, Switzerland, June 14, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments...See details»
Home - Ironwood Pharmaceuticals
Ironwood has successfully completed the tender offer of VectivBio, a global clinical-stage biotechnology company pioneering novel, transformational treatments for severe rare gastrointestinal conditions. For more information, click hereSee details»